❌

Normal view

SortedRL: Accelerating RL Training for LLMs through Online Length-Aware Scheduling

arXiv:2603.23414v1 Announce Type: cross Abstract: Scaling reinforcement learning (RL) has shown strong promise for enhancing the reasoning abilities of large language models (LLMs), particularly in tasks requiring long chain-of-thought generation. However, RL training efficiency is often bottlenecked by the rollout phase, which can account for up to 70% of total training time when generating long trajectories (e.g., 16k tokens), due to slow autoregressive generation and synchronization overhead between rollout and policy updates. We propose SortedRL, an online length-aware scheduling strategy designed to address this bottleneck by improving rollout efficiency and maintaining training stability. SortedRL reorders rollout samples based on output lengths, prioritizing short samples forming groups for early updates. This enables large rollout batches, flexible update batches, and near on-policy micro-curriculum construction simultaneously. To further accelerate the pipeline, SortedRL incorporates a mechanism to control the degree of off-policy training through a cache-based mechanism, and is supported by a dedicated RL infrastructure that manages rollout and update via a stateful controller and rollout buffer. Experiments using LLaMA-3.1-8B and Qwen-2.5-32B on diverse tasks, including logical puzzles, and math challenges like AIME 24, Math 500, and Minerval, show that SortedRL reduces RL training bubble ratios by over 50%, while attaining 3.9% to 18.4% superior performance over baseline given same amount of data.

Artificial Intelligence for Predicting Immunotherapy Efficacy in Non-Small Cell Lung Cancer

23 March 2026 at 18:00

J Inflamm Res. 2026 Mar 17;19:581764. doi: 10.2147/JIR.S581764. eCollection 2026.

ABSTRACT

Immune checkpoint inhibitors (ICIs) have significantly improved the clinical outcomes for patients with non-small cell lung cancer (NSCLC). However, patient heterogeneity and the limitations of current biomarkers contribute to variations in therapeutic responses. Identifying potential beneficiaries of immunotherapy and predicting efficacy remain critical challenges. In recent years, artificial intelligence (AI) has become increasingly applied in cancer treatment, particularly for modeling clinical data and predicting patient prognosis. By integrating multi-omics data such as radiomics, pathomics, genomics, transcriptomics, proteomics, and microbiomics, AI enables comprehensive biomarker discovery and facilitates prediction of immunotherapy responses and potential toxicities in NSCLC patients. Despite these advancements, challenges such as data standardization, limited interpretability, and technical barriers persist. This review summarizes the application of AI in predicting immunotherapy efficacy for NSCLC patients and discusses the challenges and future directions in the context of precision medicine.

PMID:41867453 | PMC:PMC13005593 | DOI:10.2147/JIR.S581764

❌